125 related articles for article (PubMed ID: 37144587)
21. Screening for cervical cancer among HIV-positive and HIV-negative women in Cameroon using simultaneous co-testing with careHPV DNA testing and visual inspection enhanced by digital cervicography: Findings of initial screening and one-year follow-up.
Cholli P; Bradford L; Manga S; Nulah K; Kiyang E; Manjuh F; DeGregorio G; Ogembo RK; Orock E; Liu Y; Wamai RG; Sheldon LK; Gona PN; Sando Z; Welty T; Welty E; Ogembo JG
Gynecol Oncol; 2018 Jan; 148(1):118-125. PubMed ID: 29153541
[TBL] [Abstract][Full Text] [Related]
22. Costs and Cost Effectiveness of Three Approaches for Cervical Cancer Screening among HIV-Positive Women in Johannesburg, South Africa.
Lince-Deroche N; Phiri J; Michelow P; Smith JS; Firnhaber C
PLoS One; 2015; 10(11):e0141969. PubMed ID: 26569487
[TBL] [Abstract][Full Text] [Related]
23. Integrating human papillomavirus testing as a point-of care service using GeneXpert platforms: Findings and lessons from a Kenyan pilot study (2019-2020).
Mwenda V; Bor JP; Nyangasi M; Njeru J; Olwande S; Njiri P; Arbyn M; Weyers S; Tummers P; Temmerman M
PLoS One; 2023; 18(5):e0286202. PubMed ID: 37228154
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of human papillomavirus-based screen-and-treat for cervical cancer prevention among HIV-infected women.
Kuhn L; Wang C; Tsai WY; Wright TC; Denny L
AIDS; 2010 Oct; 24(16):2553-61. PubMed ID: 20706107
[TBL] [Abstract][Full Text] [Related]
25. Primary HPV screening for cervical cancer: Results after two screening rounds in a regional screening program in Finland.
Veijalainen O; Kares S; Kotaniemi-Talonen L; Kujala P; Vuento R; Luukkaala T; Kholová I; Mäenpää J
Acta Obstet Gynecol Scand; 2021 Mar; 100(3):403-409. PubMed ID: 33037625
[TBL] [Abstract][Full Text] [Related]
26. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial -- the HPV FOCAL Study.
Ogilvie GS; Krajden M; van Niekerk DJ; Martin RE; Ehlen TG; Ceballos K; Smith LW; Kan L; Cook DA; Peacock S; Stuart GC; Franco EL; Coldman AJ
Br J Cancer; 2012 Dec; 107(12):1917-24. PubMed ID: 23169286
[TBL] [Abstract][Full Text] [Related]
27. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
[TBL] [Abstract][Full Text] [Related]
28. Uptake of community-based, self-collected HPV testing vs. visual inspection with acetic acid for cervical cancer screening in Kampala, Uganda: preliminary results of a randomised controlled trial.
Moses E; Pedersen HN; Mitchell SM; Sekikubo M; Mwesigwa D; Singer J; Biryabarema C; Byamugisha JK; Money DM; Ogilvie GS
Trop Med Int Health; 2015 Oct; 20(10):1355-67. PubMed ID: 26031572
[TBL] [Abstract][Full Text] [Related]
29. Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial.
Denny L; Kuhn L; Hu CC; Tsai WY; Wright TC
J Natl Cancer Inst; 2010 Oct; 102(20):1557-67. PubMed ID: 20884893
[TBL] [Abstract][Full Text] [Related]
30. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
Gilham C; Sargent A; Kitchener HC; Peto J
Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
[TBL] [Abstract][Full Text] [Related]
31. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
32. Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial.
Denny L; Kuhn L; De Souza M; Pollack AE; Dupree W; Wright TC
JAMA; 2005 Nov; 294(17):2173-81. PubMed ID: 16264158
[TBL] [Abstract][Full Text] [Related]
33. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program.
Lazcano-Ponce E; Lörincz AT; Salmerón J; Fernández I; Cruz A; Hernández P; Mejia I; Hernández-Avila M
Cancer Causes Control; 2010 Oct; 21(10):1693-700. PubMed ID: 20617376
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of higher-grade dysplasia in persistently high-risk human papillomavirus positive, cytology negative women after introduction of the new cervical cancer screening in Germany.
Berger L; Wolf-Breitinger M; Weiß C; Tuschy B; Berlit S; Sütterlin M; Spaich S
Cancer Causes Control; 2023 May; 34(5):469-477. PubMed ID: 36854989
[TBL] [Abstract][Full Text] [Related]
35. High-risk HPV testing vs liquid-based cytology for cervical cancer screening among 25- to 30-year-old women: A historical cohort study.
Feldstein O; Gali-Zamir H; Schejter E; Feinberg T; Yehuda-Shnaidman E; Bornstein J; Levy T
Acta Obstet Gynecol Scand; 2023 Feb; 102(2):226-233. PubMed ID: 36478537
[TBL] [Abstract][Full Text] [Related]
36. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
37. Performance of Cervical Cancer Screening Techniques in HIV-Infected Women in Uganda.
Bansil P; Lim J; Byamugisha J; Kumakech E; Nakisige C; Jeronimo JA
J Low Genit Tract Dis; 2015 Jul; 19(3):215-9. PubMed ID: 25551591
[TBL] [Abstract][Full Text] [Related]
38. Performance of visual Inspection With Acetic Acid for Cervical Cancer Screening as Compared to Human papillomavirus Deoxyribonucleic acid Testing Among Women With HIV in Ethiopia: A Comparative Cross-sectional Study.
Bogale AL; Teklehaymanot T; Kassie GM; Medhin G; Ali JH; Belay NB
Cancer Control; 2022; 29():10732748221114980. PubMed ID: 35829643
[TBL] [Abstract][Full Text] [Related]
39. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
[TBL] [Abstract][Full Text] [Related]
40. A Randomized Clinical Trial of Human Papillomavirus Test-and-Treat as Compared to Cytology-Based Screening for Prevention of Cervical Cancer Among Women With Human Immunodeficiency Virus: AIDS Clinical Trials Group Protocol A5282.
Wilkin T; Chen H; Sahasrabuddhe V; Matining R; Mngqibisa R; Chinula L; Mbilizi Y; Magure T; Omoz-Oarhe AE; Rassool M; Riviere C; Bhosale R; Godbole S; Naranjo R; Coombs R; Michelow P; Godfrey C; Firnhaber C
Clin Infect Dis; 2022 Oct; 75(8):1280-1288. PubMed ID: 35294524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
